

LA JOLLA PHARMACEUTICAL CO

Form 8-K

May 12, 2003

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): May 12, 2003

**LA JOLLA PHARMACEUTICAL COMPANY**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

---

(State or Other Jurisdiction of  
Incorporation)

---

(Commission File Number)

---

(IRS Employer Identification No.)

6455 Nancy Ridge Drive  
San Diego, California 92121  
(Address of Principal Executive Offices, Including Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

---

---

---

**TABLE OF CONTENTS**

Item 9. Regulation FD Disclosure.

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 9. Regulation FD Disclosure.**

The information contained in this Item 9 is being furnished pursuant to Item 12 of Form 8-K, Results of Operations and Financial Condition, in accordance with the interim guidance provided by the Securities and Exchange Commission in Release No. 33-8216 issued March 27, 2003.

On May 12, 2003, La Jolla Pharmaceutical Company (the Company ) issued a news release reporting the financial results of the Company for its first fiscal quarter. A copy of the news release is attached to this report as Exhibit 99.1.

The information in this Current Report, including the exhibit attached hereto, is being furnished and shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

**Item 12. Results of Operations and Financial Condition.**

The information under this caption is furnished by the Company under Item 9 in place of Item 12 of Form 8-K in accordance with the interim guidance provided by the Securities and Exchange Commission in Release No. 33-8216 issued March 27, 2003.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2003

**LA JOLLA PHARMACEUTICAL COMPANY**

By:           /s/ Steven B. Engle          

Steven B. Engle  
Chairman of the Board and  
Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release